ERBB2 and neoplasm: Despite the observed lack of pre‐treatment aspirin survival benefit in the trastuzumab‐resistant HCC1954 model of Her2+ BC, we did observe a delayed time to primary tumour recurrence, and time to metastasis in the MDA‐MB‐231/LM2‐4/H2N Her2+ BC model treated with 120 mg/kg aspirin.